Open Access

Lewis(y) antigen promotes the progression of epithelial ovarian cancer by stimulating MUC1 expression

  • Authors:
    • Rui Hou
    • Luo Jiang
    • Dawo Liu
    • Bei Lin
    • Zhenhua Hu
    • Jian Gao
    • Danye Zhang
    • Shulan Zhang
    • Masao Iwamori
  • View Affiliations

  • Published online on: June 2, 2017     https://doi.org/10.3892/ijmm.2017.3009
  • Pages: 293-302
  • Copyright: © Hou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MUC1 is a type I transmembrane glycoprotein and is overexpressed in various epithelial tumor tissues. Some researchers have demonstrated that the glycosylation status of MUC1 can affect MUC1-mediated tumor growth and cell differentiation. In our previous study, we proved that the abilities of cell proliferation, adhesion, invasion and metastasis, and drug resistance were enhanced in ovarian cancer cells stably expressing Lewis(y). Therefore, we hypothesized that Lewis(y) antigen may play a central role in regulating MUC1 expression, and MUC1-mediated cell growth and differentiation may be closely associated with Lewis(y) antigen. This study aimed to examine the correlation between MUC1 expression and Lewis(y) antigen levels in ovarian cancer cell lines and tissue samples. A series of techniques, including RT-qPCR, western blot anlaysis, immunoprecipitation, immunohistochemistry and double-labeling immunofluorescence were applied to detect the expression of Lewis(y) and MUC1. In malignant epithelial ovarian tumors, the positive expression rates of Lewis(y) antigen and MUC1 were 88.33 and 86.67%, respectively, which were markedly higher than those in borderline (60.00 and 53.33%, P<0.05), benign (33.33 and 30%, P<0.01) and normal (0 and 25%, P<0.01) ovarian samples. There was no correlation between the positive expression rates of Lewis(y) or MUC1 and clinicopathological parameters in ovarian cancers (P>0.05). The expression levels of Lewis(y) and MUC1 correlated with the clinical FIGO stage (P<0.05). Both MUC1 and Lewis(y) were highly expressed in ovarian cancer tissues, and their expression levels were positively correlated (P<0.01). In α1,2-fucosyltransferase (α1,2-FT)-transfected cells, the gene and protein expression levels of MUC1 were significantly upregulated compared with the cells that did not overexpress α1,2-FT (P<0.05). The ratio of Lewis(y) immunoprecipitated with MUC1 to total MUC1 increased 1.55-fold in α1,2-FT-overexpressing cells (P<0.05). The overexpression of Lewis(y) resulted in the upregulation of MUC1. On the whole, our data indicate that both MUC1 and Lewis(y) are associated with the occurrence and development of ovarian cancers.
View Figures
View References

Related Articles

Journal Cover

August-2017
Volume 40 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hou R, Jiang L, Liu D, Lin B, Hu Z, Gao J, Zhang D, Zhang S and Iwamori M: Lewis(y) antigen promotes the progression of epithelial ovarian cancer by stimulating MUC1 expression. Int J Mol Med 40: 293-302, 2017
APA
Hou, R., Jiang, L., Liu, D., Lin, B., Hu, Z., Gao, J. ... Iwamori, M. (2017). Lewis(y) antigen promotes the progression of epithelial ovarian cancer by stimulating MUC1 expression. International Journal of Molecular Medicine, 40, 293-302. https://doi.org/10.3892/ijmm.2017.3009
MLA
Hou, R., Jiang, L., Liu, D., Lin, B., Hu, Z., Gao, J., Zhang, D., Zhang, S., Iwamori, M."Lewis(y) antigen promotes the progression of epithelial ovarian cancer by stimulating MUC1 expression". International Journal of Molecular Medicine 40.2 (2017): 293-302.
Chicago
Hou, R., Jiang, L., Liu, D., Lin, B., Hu, Z., Gao, J., Zhang, D., Zhang, S., Iwamori, M."Lewis(y) antigen promotes the progression of epithelial ovarian cancer by stimulating MUC1 expression". International Journal of Molecular Medicine 40, no. 2 (2017): 293-302. https://doi.org/10.3892/ijmm.2017.3009